Certara, INC Form 4 insider transactions

James E. Cashman III, a director at Certara, Inc., reported the vesting and conversion of restricted stock units into common stock, as well as the grant of additional restricted stock units.

Director Eran Broshy reports acquisition and disposal of Certara, Inc. common stock and restricted stock units.

Rona Anhalt, Chief Human Resources Officer of Certara, Inc., reports the acquisition of performance stock units and restricted stock units.

Daniel Corcoran, SVP and General Counsel of Certara, Inc., reports the acquisition of performance stock units and restricted stock units on May 20, 2025, under the company's incentive plans.

Leif E. Pedersen, President and Chief Commercial Officer of Certara, Inc., reports the acquisition of performance stock units and restricted stock units.

Adrian McKemey, President of Drug Development Solutions at Certara, Inc., reports the acquisition of performance stock units and restricted stock units.

John E. Gallagher, CFO of Certara, Inc., reports the acquisition of performance stock units and restricted stock units under the company's incentive plans.

Robert Aspbury, President of Predictive Technologies at Certara, Inc., reports the acquisition of performance stock units and restricted stock units.

Certara's CEO, William Feehery, received performance stock units (PSUs) and restricted stock units (RSUs) on May 20, 2025, under the company's incentive plans.

Robert Aspbury, President of Predictive Technologies at Certara, Inc., reports the acquisition and disposal of common stock related to the vesting and settlement of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).

Leif E. Pedersen, President and Chief Commercial Officer of Certara, Inc., reports the acquisition and disposal of common stock and restricted stock units related to vesting and tax obligations.

John E. Gallagher, President and Chief Commercial Officer of Certara, Inc., reports the vesting and disposal of restricted stock units to cover tax obligations.

William Feehery, CEO of Certara, Inc., reports transactions involving common stock and restricted stock units.

Director John V. W. Reynders was granted 10,709 restricted stock units (RSUs) of Certara, Inc. on October 16, 2024, under the company's 2020 Incentive Plan.

Patrick F. Smith, President of Drug Development Solutions at Certara, Inc., sold 5,409 shares of common stock at $11.03 per share on October 7, 2024, under a pre-arranged 10b5-1 trading plan.

Patrick F. Smith, President of Drug Development Solutions at Certara, Inc., reports the vesting and settlement of restricted stock units and related tax withholding.

Leif E. Pedersen, President and Chief Commercial Officer of Certara, Inc., sold 51,224 shares of common stock at a price of $11.29 per share on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Robert Aspbury, President of Scientific Software at Certara, Inc., reports the withholding of shares to cover tax obligations related to vested restricted stock units.

Daniel Corcoran, SVP and General Counsel of Certara, Inc., reports the acquisition of restricted stock units (RSUs) under the company's 2020 Incentive Plan.

Rona Anhalt, Chief Human Resources Officer of Certara, Inc., reported the acquisition of 21,440 Restricted Stock Units (RSUs) on June 1, 2024, according to a Form 4 filing with the SEC.

Director Matthew Walsh reports the vesting and conversion of restricted stock units (RSUs) into common stock, as well as the grant of additional RSUs.

Nancy Killefer, a director at Certara, Inc., reports the vesting and conversion of restricted stock units (RSUs) into common stock, as well as the grant of additional RSUs.

Director Rosemary Crane reports the vesting and conversion of restricted stock units (RSUs) into common stock, as well as the grant of additional RSUs.

Director Cynthia Collins reports the vesting and conversion of restricted stock units into common stock, as well as the grant of additional restricted stock units.

James E. Cashman III, a director at Certara, Inc., reported the vesting and conversion of restricted stock units into common stock, as well as the grant of additional restricted stock units.

Director Eran Broshy reports acquisition of shares through RSU vesting and grant, as well as disposition of shares through RSU conversion.

William F. Feehery, CEO of Certara, Inc., files an amended SEC Form 4 to correct the number of restricted stock units (RSUs) granted on April 1, 2024.

Patrick F. Smith, President of Drug Development Solutions at Certara Inc., sold shares of common stock on April 2, 2024, under a pre-arranged 10b5-1 trading plan.

Richard M. Traynor, SVP and General Counsel of Certara, Inc., reports transactions involving common stock and restricted stock units, including vesting, tax withholding, and sales under a Rule 10b5-1 trading plan.

Patrick F. Smith, President of Drug Development Solutions at Certara, Inc., reports transactions involving restricted stock units and common stock, resulting in adjustments to his beneficial ownership.